Coveo (CVO) acquires Anglera as core SaaS revenue grows 12%, but $14.9m cash outflow raises questions
Read More Pharma Industry News Is Johnson & Johnson quietly building a new autoimmune franchise around FcRn inhibition? Johnson & Johnson is expanding nipocalimab into multiple autoimmune indications. Find out if FcRn inhibition is the foundation of its next blockbuster franchise. bySrinathOctober 30, 2025